Autopsy report · NCT05662670

A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer

“Due to the adjustment of the R\&D strategy, Suzhou Junjing Biosciences Co., Ltd. decided to terminate this study in September 2023”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 6 months before it stopped.
• 14 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Suzhou Junjing BioSciences Co., Ltd.

Sponsor type

Industry

Conditions

Locally Advanced or Metastatic NSCLC

Interventions

WJ13404 tablets

Participants

14

Sites

1

Countries

China

Trials that died the same way

• Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
  “Based on the adjustment of the sponsor's R\&D strategy, it is decided to terminate this study in advance.” (64% match in meaning)
• Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
  “US FDA is streamlining the Biosimilar development. Thus, Biocon decided to terminate the study.” (61% match in meaning)
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）
  “Due to adjustments in the sponsor's development strategy, it has been decided to terminate the study.” (59% match in meaning)
• Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
  “The decision was made to terminate this study to further enrollment, as of 08 March 2022. The decision was made primarily due to a change in development strategy.” (59% match in meaning)
• A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain
  “The company decided to cancel this study in conformity with PH FDA Circular 2013-004” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.